Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. Show more
Location: 855 Oak Grove Avenue, Menlo Park, CA, 94025, United States | Website: https://orukatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
578.2M
52 Wk Range
$5.49 - $31.13
Previous Close
$15.44
Open
$15.45
Volume
86,306
Day Range
$14.73 - $15.45
Enterprise Value
257M
Cash
328.4M
Avg Qtr Burn
-23.98M
Insider Ownership
3.82%
Institutional Own.
93.19%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ORKA-001 Details Psoriasis | Phase 2a Data readout | |
ORKA-002 Details Psoriasis | Phase 1 Data readout |